MUC16 and ovarian carcinoma: confirmed the significant cytotoxicity of MUC16 ectodomain-specific bispecific single-chain variable fragments (BiTEDs) against ovarian cancer cells in vitro, effectively delaying tumor progression in vivo, especially when combined with anti-angiogenic treatment, showing potential for extending survival (147).